the worker's performance whilst at work due to ill health (i.e. presenteeism). A number of global measures have been developed to assess presenteeism in clinical studies. However, limited information is available on the correlation between these measures and the construct validity of these measures. Objectives: To i) determine the correlation between four global measures of presenteeism and ii) to evaluate the construct validity of these measures. Methods: The main aim of this international observational study (7 countries in Europe and Canada), recruiting patients with IA (RA, PsA or AS) or OA in paid employment, was to investigate content and construct validity of global presenteeism measures. Patients completed 4 global measures (Work Productivity Scale -Arthritis (WPS-A), Work Productivity and Activity Impairment Questionnaire (WPAI), Work Ability Index (WAI), and both the Quality and Quantity scales of the QQ questionnaire) (see table legend for descriptions individual scales). Spearman correlations were applied to test the correlation between individual presenteeism scales and to test construct validity with the 11-item Workplace Activity Limitation presenteeism Scale (WALS) and several health related patient reported outcome measures. Interpretation of correlation coefficients: (very) Background: According to previous studies, serum amyloid A (SAA) is involved in the pathophysiology of several conditions including inflammatory arthritis and psoriasis. Recent evidence suggests its valuable role in monitoring disease activity in Rheumatoid Arthritis, but its role is yet to be determined in Psoriatic Arthritis (PsA). Objectives: To study the association between SAA levels and its variation with other biomarkers and disease activity/functional parameters in a cohort of PsA patients under biologic therapy. Methods: Observational retrospective study was conducted including PsA patients (according to CASPAR criteria) followed at our Rheumatology department with at least one measurement of SAA levels from January 2015 until December 2016. Demographic and clinical data were obtained by consulting the national database (Reuma.pt). The disease activity/functional scores from at least one visit and corresponding measurements of SAA, ESR and CRP levels were collected. The difference ( ) between 2 evaluations separated by a median time of 6 months [6][7][8][9][10][11][12][13][14][15][16][17][18] was calculated for all variables. Agreement between dichotomized biomarkers was calculated using kappa coefficients. Correlations were studied using Pearson and Spearman coefficient analysis. Significance level was set as 0.05. Results: 53 PsA patients were included. 31 (59%) patients were females with a mean (SD) age of 50 (11.2) years and a median disease duration of 9 years . 28% had axial involvement, 34% peripheral involvement and 38% had both types. All patients were under biologic DMARD. 100 SAA measurements were collected. Median SAA and ESR levels were significantly superior in female patients (23 vs 6mm/1sth and 8.6 vs 4.4mg/L, respectively, p<0.05) and only ESR levels correlated with age (r=0.20, p=0.05). The three biomarkers showed a weak association with serum creatinine levels, with greater correlation for SAA (r=0.46, p<0.001). SAA levels had a stronger correlation with CRP (r=0.75, p<0.001) than with ESR levels (r=0.26, p<0.01). SAA and CRP (dichotomized as negative/positive) had a greater level of agreement (κ=0.40) compared to ESR (κ=0.26 and κ=0.32, respectively). No significant correlations were found between the biomarkers and the tender/swollen joint count or the pain/global disease activity VAS. SAA levels correlated with ASDAS CRP (r=0.43, p<0.001) and weakly with ASDAS ESR and DAS28 CRP (r=0.20 and r=0.24, respectively, p<0.05). Only ESR had a significant weak correlations with BASDAI, MASES and SPARCC scores (r=0.25, r=0.21, r=0.35; p<0.05). All the biomarkers had weak correlations with BASFI and HAQ scores. SAA levels had a weak correlation with CRP (r=0.32, p=0.03; n=47) and no significant association was found with ESR. SAA correlated significantly with ASDAS CRP and BASMI (r=0.32, r=0.39; p<0.05).
THU0690 SERUM AMYLOID A LEVELS AS A POTENTIAL BIOMARKER TO MONITOR PSORIATIC ARTHRITIS PATIENTS ON BIOLOGICS -A RETROSPECTIVE OBSERVATIONAL STUDY
T. Martins Rocha, R. Fonseca, D. Rosa-Goncalves, F. Aguiar, R. Ferreira, A. Bernardo, M. Bernardes, L. Costa. Rheumatology, Centro Hospitalar de São João, Porto, Portugal Background: According to previous studies, serum amyloid A (SAA) is involved in the pathophysiology of several conditions including inflammatory arthritis and psoriasis. Recent evidence suggests its valuable role in monitoring disease activity in Rheumatoid Arthritis, but its role is yet to be determined in Psoriatic Arthritis (PsA). Objectives: To study the association between SAA levels and its variation with other biomarkers and disease activity/functional parameters in a cohort of PsA patients under biologic therapy. Methods: Observational retrospective study was conducted including PsA patients (according to CASPAR criteria) followed at our Rheumatology department with at least one measurement of SAA levels from January 2015 until December 2016. Demographic and clinical data were obtained by consulting the national database (Reuma.pt). The disease activity/functional scores from at least one visit and corresponding measurements of SAA, ESR and CRP levels were collected. The difference ( ) between 2 evaluations separated by a median time of 6 months [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] was calculated for all variables. Agreement between dichotomized biomarkers was calculated using kappa coefficients. Correlations were studied using Pearson and Spearman coefficient analysis. Significance level was set as 0.05. Results: 53 PsA patients were included. 31 (59%) patients were females with a mean (SD) age of 50 (11.2) years and a median disease duration of 9 years . 28% had axial involvement, 34% peripheral involvement and 38% had both types. All patients were under biologic DMARD. 100 SAA measurements were collected. Median SAA and ESR levels were significantly superior in female patients (23 vs 6mm/1sth and 8.6 vs 4.4mg/L, respectively, p<0.05) and only ESR levels correlated with age (r=0.20, p=0.05). The three biomarkers showed a weak association with serum creatinine levels, with greater correlation for SAA (r=0.46, p<0.001). SAA levels had a stronger correlation with CRP (r=0.75, p<0.001) than with ESR levels (r=0.26, p<0.01). SAA and CRP (dichotomized as negative/positive) had a greater level of agreement (κ=0.40) compared to ESR (κ=0.26 and κ=0.32, respectively) . No significant correlations were found between the biomarkers and the tender/swollen joint count or the pain/global disease activity VAS. SAA levels correlated with ASDAS CRP (r=0.43, p<0.001) and weakly with ASDAS ESR and DAS28 CRP (r=0.20 and r=0.24, respectively, p<0.05). Only ESR had a significant weak correlations with BASDAI, MASES and SPARCC scores (r=0.25, r=0.21, r=0.35; p<0.05) . All the biomarkers had weak correlations with BASFI and HAQ scores. SAA levels had a weak correlation with CRP (r=0.32, p=0.03; n=47) and no significant association was found with ESR. SAA correlated significantly with ASDAS CRP and BASMI (r=0.32, r=0.39; p<0.05).
Conclusions:
This study showed that SAA levels and its variation had a significant correlation with CRP levels and its variation, respectively. Significant association with ASDAS CRP variations suggests that serial measurements of SAA may represent an additional marker for monitoring disease activity over time in PsA patients. Background: Quantitating the degree of inflammation has become essential to tailor the treatment strategy of various rheumatic diseases. Traditionally used measures to assess disease activity and treatment response in spondyloarthritis (SpA) are ESR, CRP and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS). Serum amyloid A (SAA) is an acute-phase reactant predominantly synthesized in the liver by hepatocytes in response to proinflammatory cytokines. Some studies have shown that SAA can be a valuable indicator of disease activity, damage and functional impairment, however it has not been extensively used in clinical practice. Objectives: To investigate if SAA levels have better correlation with conventional assessments used to monitor anti-tumor necrosis factorα (anti-TNF) treatment in SpA than CRP and ESR. Methods: Prospective study, including SpA patients under anti-TNFα treatment at a Rheumatology Department of a Portuguese Universitary Hospital. The following parameters were collected and registered in two different evaluations 6 months apart from each other: SAA, CRP and ESR levels, BASDAI, ASDAS-PCR, ASDAS-VS, BASFI, BASMI, swollen and tender joints counts (SJC and TJC), MASES, SPARCC, and patient global assessment (PtGA), physician global assessment (PGA), total back pain (TBP), nocturnal back pain (NBP) measured in a visual analogue scale (VAS). The variation of each parameter was calculated as the difference between the levels registered at each evaluation (baseline and 6 months) and presented as (parameter). We compared the correlation between SAA, CRP and ESR levels with BASDAI, ASDAS-PCR, ASDAS-VS, BASFI, BASMI, SJC, TJC, MASES, SPARCC, PtGA-VAS, PGA-VAS, TBP-VAS, NBP-VAS. The statistical analysis was performed using SPSS 21.0 software, and p<0.05 was taken to indicate statistical significance. Correlation was calculated using the Spearman rank correlation (r). Results: 89 patients were included, 58.4% (n=52) were male. On baseline the median age was 44.0 years (range 21.0-74.6) and median disease duration was 18.8 years (2-51.6). SAA was moderately correlated with CRP (r=0.65, p<0.001) and had lower correlation with ESR (r=0.28, p=0.009). SAA correlated with NBP-VAS (r=0.260, p=0.016), but ESR and CRP did not correlate with this parameter. We also found statistically significant correlation between SAA and ASDAS-VS (r=0.257, p=0.017), ASDAS-CRP (r=0.387, p<0.001), BASFI (r=0.301, p=0.005) . CRP also showed significant correlation with BASFI, but it was weaker than that observed with SAA (r=0.230, p=0.033). There was no statistically significant correlation between SAA levels and MASES, although CRP had a weak correlation (r=0.217, p=0.041). There was no significant correlation between neither SAA, CRP or ESR and the following parameters: TBP-VAS, PtGA-VAS, PGA-VAS BASDAI, BASMI, SPARCC, TJC or SJC. Conclusions: This study suggests that SAA can be an useful tool in monitoring treatment with anti-TNFα and that could be introduced in clinical practice. However more studies, with larger sample sizes, should be undertaken to better assess this subject. Background: Rheumatoid arthritis (RA) can have a major impact on health related quality of life (HRQoL). The revised AIMS-2 is the main outcome measure that has been used for measuring HRQoL in patients with rheumatic diseases. Guillemin et al. developed a short form of AIMS-2 (AIMS-2 SF) (1) which is more practical and less time consuming compared to AIMS-2. Objectives: The purpose of this study was to investigate validity and reliability of the Turkish version of AIMS2-SF (TR AIMS-2 SF). Methods: Turkish AIMS2-SF was developed after translation and back-translation method. Culturally adapted version preserved 5 component-structure (upper limb function, lower limb function, affect, pain and social interaction) with 26 items according to the original article (1). Subjects fulfilling ACR/EULAR 2010 classification criteria for RA were consecutively enrolled into the study. Patients with malignancy, fibromyalgia syndrome and other systemic inflammatory diseases were excluded. Demographic data, the body mass index (BMI), severity of pain (VAS), disease duration (month) and other clinical features was evaluated. Reliability was investigated with test-retest reliability (intraclass correlation coefficient-ICC) and internal consistency (Cronbach's alpha). Spearman's rank correlation coefficient was used to evaluate the relation between quantitative parameters and the validity. Construct validity was assessed by the correlation of TR AIMS2-SF with other clinical parameters (age, disease duration, VAS pain, DAS-28) and functional parameters such as Nottingham Health Profile (NHP), Health Assessment Questionnaire (HAQ), Beck Depression Inventory (BDI), Duruoz Hand Index (DHI). Statistical analyses were performed with SPSS version 20 and a value of p<0.05 was considered as statistically significant. Results: Sixty patients (6 males) were recruited into the study. The mean ± standart deviation (SD) of age (years) and disease duration (months) were 51.8±12.5 and 71.4±69.3, respectively. Mean scores of TR AIMS2-SF were; upper limb function 7.3±6.9, lower limb function 7.7±4.7, affect 7.4±3.2, pain 6±3.1, social interaction 4±2.3 and total score 35.5±16.6. The floor and ceiling effects of TR AIMS2-SF were 1.6 and 3.3, respectively. Both Cronbach's alpha and ICC were 0.83 indicating good reliability. There was significant correlation (rho, p value) with parameters that were directly related to HRQoL which were NHP subscales (energy level: 0.46, pain: 0.63, emotional reaction: 0.55, sleep 0.33, social interaction: 0.60, physical activity: 0.63; p<0.0001), HAQ (0.70, p<0.0001), BDI (0.54, p<0.0001), DHI (0.60, p<0.0001). Poor or not significant correlation was found with parameters that were not directly related to HRQoL such as age (-0.004, p=0.97) , disease duration (0.21, p=0.09), vas pain (0.37, p<0.05); on the other hand, disease activity (DAS-28) correlated moderate (0.49, p<0.0001). Conclusions: Turkish version of AIMS2-SF is a reliable and valid tool that can be used to evaluate the quality of life in RA. This is a feasible measure that can be used in daily practice easily. 
